170 related articles for article (PubMed ID: 36259229)
41. Methotrexate-induced pancytopenia: a case series of 46 patients.
Ajmani S; Preet Singh Y; Prasad S; Chowdhury A; Aggarwal A; Lawrence A; Misra R; Mishra R; Agarwal V
Int J Rheum Dis; 2017 Jul; 20(7):846-851. PubMed ID: 28261918
[TBL] [Abstract][Full Text] [Related]
42. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
Hornung N; Ellingsen T; Stengaard-Pedersen K; Poulsen JH
J Rheumatol; 2004 Dec; 31(12):2374-81. PubMed ID: 15570637
[TBL] [Abstract][Full Text] [Related]
43. Oral fumaric acid esters for psoriasis.
Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
[TBL] [Abstract][Full Text] [Related]
44. Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.
Liu L; Liu S; Wang C; Guan W; Zhang Y; Hu W; Zhang L; He Y; Lu J; Li T; Liu X; Xuan Y; Wang P
J Clin Rheumatol; 2019 Aug; 25(5):197-202. PubMed ID: 29975207
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.
Hoekstra M; van Ede AE; Haagsma CJ; van de Laar MA; Huizinga TW; Kruijsen MW; Laan RF
Ann Rheum Dis; 2003 May; 62(5):423-6. PubMed ID: 12695153
[TBL] [Abstract][Full Text] [Related]
46. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.
Morgan SL; Baggott JE; Lee JY; Alarcón GS
J Rheumatol; 1998 Mar; 25(3):441-6. PubMed ID: 9517760
[TBL] [Abstract][Full Text] [Related]
47. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.
Ortiz Z; Shea B; Suarez-Almazor ME; Moher D; Wells GA; Tugwell P
J Rheumatol; 1998 Jan; 25(1):36-43. PubMed ID: 9458200
[TBL] [Abstract][Full Text] [Related]
48. A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate.
Stamp LK; OʼDonnell JL; Frampton C; Drake J; Zhang M; Barclay M; Chapman PT
J Clin Rheumatol; 2019 Oct; 25(7):284-287. PubMed ID: 30001258
[TBL] [Abstract][Full Text] [Related]
49. Does daily folic acid supplementation reduce methotrexate efficacy?
Cline A; Jorizzo JL
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447631
[TBL] [Abstract][Full Text] [Related]
50. Low-dose weekly oral methotrexate therapy for inflammatory arthritis.
Boh LE; Schuna AA; Pitterle ME; Adams EM; Sundstrom WR
Clin Pharm; 1986 Jun; 5(6):503-8. PubMed ID: 3720217
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
52. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
53. Folate supplementation during methotrexate therapy for patients with psoriasis.
Strober BE; Menon K
J Am Acad Dermatol; 2005 Oct; 53(4):652-9. PubMed ID: 16198787
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
[TBL] [Abstract][Full Text] [Related]
55. Methotrexate in psoriatic arthritis.
Cutolo M; Seriolo B; Pizzorni C; Craviotto C; Sulli A
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S76-80. PubMed ID: 12463453
[TBL] [Abstract][Full Text] [Related]
56. [Reducing toxicity of methotrexate with folic acid].
Harten P
Z Rheumatol; 2005 Jun; 64(5):353-8. PubMed ID: 15965822
[TBL] [Abstract][Full Text] [Related]
57. Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.
Yan K; Zhang Y; Han L; Huang Q; Zhang Z; Fang X; Zheng Z; Yawalkar N; Chang Y; Zhang Q; Jin L; Qian D; Li X; Wu M; Xu Q; Zhang X; Xu J
JAMA Dermatol; 2019 Mar; 155(3):327-334. PubMed ID: 30698628
[TBL] [Abstract][Full Text] [Related]
58. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.
Rademaker M; Gupta M; Andrews M; Armour K; Baker C; Foley P; Gebauer K; George J; Rubel D; Sullivan J
Australas J Dermatol; 2017 Aug; 58(3):166-170. PubMed ID: 27402434
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
Singh SK; Singnarpi SR
Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
[TBL] [Abstract][Full Text] [Related]
60. Adverse effects of methotrexate in three psoriatic arthritis patients.
Maejima H; Watarai A; Nakano T; Katayama C; Nishiyama H; Katsuoka K
Rheumatol Int; 2014 Apr; 34(4):571-4. PubMed ID: 23274445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
